Clinical Trials Logo

Clinical Trial Summary

Major liver resection is associated with substantial intraoperative blood loss and subsequently blood transfusions. Blood transfusion in elective liver surgery is a significant factor of perioperative morbidity and mortality, as well as possibly long-term oncologic outcome. The purpose of this study is to use whole blood phlebotomy to decrease the central venous pressure, resulting in a state of relative hypovolemia. It is hypothesized that this intervention will lead to a decrease in blood loss at the time of liver resection and thus reduced blood transfusion in major liver surgeries.


Clinical Trial Description

Major liver resection is associated with significant intraoperative blood loss and blood transfusions. Blood transfusion in elective liver surgery is a key determinant of perioperative morbidity and mortality, as well as possibly long-term oncologic outcome. Whole blood phlebotomy is a simple intervention, whose aim is to decrease the central venous pressure yielding a state of relative hypovolemia and thus lead to decreased blood loss and subsequently blood transfusion. Small studies, mostly from the liver transplant literature, would suggest that phlebotomy with controlled hypovolemia can result in decreased blood loss and blood transfusion. Since blood loss is an important issue in liver surgery, and the benefits of phlebotomy and controlled hypovolemia are unknown in liver resection patients, a rigorously conducted trial in a representative population of patients undergoing liver resection is warranted, and feasible. In this proposal, it is hypothesized that by the use of hypovolemic phlebotomy, it is possible to decrease blood loss and blood transfusions. To test this hypothesis the investigators plan to randomly allocate participants to hypovolemic phlebotomy plus standard of care or to standard of care. Participants will be those patients undergoing elective major liver resection at The Ottawa Hospital, le Centre Hospitalier de l'Université de Montréal, and le Centre Hospitalier de l'Université de Sherbrooke for any indication. The primary outcome will be red blood cells transfusion up to 30 days following surgery. Secondary outcomes will include intraoperative blood loss, other blood product transfusion requirements, perioperative morbidity and mortality, safety, physiologic parameters, and feasibility elements. A total of 440 patients will be randomized across the 3 sites in Ontario and Quebec. The efficacy of phlebotomy in terms of blood loss and transfusion prevention will be assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03651154
Study type Interventional
Source Ottawa Hospital Research Institute
Contact
Status Active, not recruiting
Phase N/A
Start date September 28, 2018
Completion date March 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03592550 - The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
Not yet recruiting NCT02521129 - A New Track Ablation Device for Liver Biopsy: A Feasibility Study Phase 1/Phase 2
Not yet recruiting NCT02168608 - Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy N/A
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Active, not recruiting NCT01177007 - Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Phase 2
Completed NCT00788697 - SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Phase 3
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1
Terminated NCT00051532 - Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma N/A
Completed NCT00001587 - A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Phase 1
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03289273 - Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Terminated NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma Phase 1
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT01744054 - Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization Phase 1
Active, not recruiting NCT02969096 - Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma Phase 2
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3